FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327694242> ?p ?o ?g. }

• W4327694242 endingPage "138" @default.
• W4327694242 startingPage "123" @default.
• W4327694242 abstract "Purpose Neoadjuvant radiation therapy (RT) with standard techniques (ST) offers a modest benefit in retroperitoneal sarcoma (RPS). As the high-risk region (HRR) at risk for a positive surgical margin and recurrence is posterior and away from radiosensitive organs at risk, using a simultaneous integrated boost (SIB) allows targeted dose escalation to the HRR while sparing these organs. We hypothesized that neoadjuvant SIB RT can improve disease control compared with ST, without increasing toxicity. Methods and Materials We retrospectively identified patients with resectable nonmetastatic RPS from 2000 to 2021 who received neoadjuvant RT of 180 to 200 cGy/fraction to standard volumes. SIB patients received 205 to 230 cGy/fraction to the appropriate HRR. Clinical endpoints included abdominopelvic control (APC), recurrence-free survival (RFS), overall survival (OS), and acute toxicity. Results With a median follow-up of 57 months (95% confidence interval [CI], 50-64), there were 103 patients with RPS who received either ST (n = 69) or SIB (n = 34) RT. Median standard volume dose was 5000 cGy (ST) and 4500 cGy (SIB), with a median HRR SIB dose of 5750 cGy. Liposarcomas (79% vs 53%; P = .004) and cT4 tumors (59% vs 19%; P < .001) were more common in the SIB cohort, without a significant difference in the rate of resection (82% vs 81%; P = .88) or R1 margin (53.5% vs 50%; P = .36); there were no R2 resections. SIB was associated with a significant improvement in 5-year APC (96% vs 70%; P = .046) and RFS (60.2% vs 36.3%; P = .036), with a nonsignificant OS difference (90.1% vs 67.5%; P = .164). On multivariable analysis, SIB remained a predictor for APC (hazard ratio, 0.07; 95% CI, 0.01-0.74; P = .027) and RFS (hazard ratio, 0.036; 95% CI, 0.13-0.98; P = .045). SIB showed no significant detriment in toxicity, albeit with a lower rate of overall grade 3 acute toxicity (3% vs 22%; P = .023) compared with ST. Conclusions In RPS, dose escalation with neoadjuvant SIB RT may be independently associated with improved APC and RFS, without a detriment in toxicity, compared with ST. With the addition of standard RT having only a modest benefit compared with surgery alone, our study suggests that future prospective studies evaluating for the benefit of SIB RT should be considered. Neoadjuvant radiation therapy (RT) with standard techniques (ST) offers a modest benefit in retroperitoneal sarcoma (RPS). As the high-risk region (HRR) at risk for a positive surgical margin and recurrence is posterior and away from radiosensitive organs at risk, using a simultaneous integrated boost (SIB) allows targeted dose escalation to the HRR while sparing these organs. We hypothesized that neoadjuvant SIB RT can improve disease control compared with ST, without increasing toxicity. We retrospectively identified patients with resectable nonmetastatic RPS from 2000 to 2021 who received neoadjuvant RT of 180 to 200 cGy/fraction to standard volumes. SIB patients received 205 to 230 cGy/fraction to the appropriate HRR. Clinical endpoints included abdominopelvic control (APC), recurrence-free survival (RFS), overall survival (OS), and acute toxicity. With a median follow-up of 57 months (95% confidence interval [CI], 50-64), there were 103 patients with RPS who received either ST (n = 69) or SIB (n = 34) RT. Median standard volume dose was 5000 cGy (ST) and 4500 cGy (SIB), with a median HRR SIB dose of 5750 cGy. Liposarcomas (79% vs 53%; P = .004) and cT4 tumors (59% vs 19%; P < .001) were more common in the SIB cohort, without a significant difference in the rate of resection (82% vs 81%; P = .88) or R1 margin (53.5% vs 50%; P = .36); there were no R2 resections. SIB was associated with a significant improvement in 5-year APC (96% vs 70%; P = .046) and RFS (60.2% vs 36.3%; P = .036), with a nonsignificant OS difference (90.1% vs 67.5%; P = .164). On multivariable analysis, SIB remained a predictor for APC (hazard ratio, 0.07; 95% CI, 0.01-0.74; P = .027) and RFS (hazard ratio, 0.036; 95% CI, 0.13-0.98; P = .045). SIB showed no significant detriment in toxicity, albeit with a lower rate of overall grade 3 acute toxicity (3% vs 22%; P = .023) compared with ST. In RPS, dose escalation with neoadjuvant SIB RT may be independently associated with improved APC and RFS, without a detriment in toxicity, compared with ST. With the addition of standard RT having only a modest benefit compared with surgery alone, our study suggests that future prospective studies evaluating for the benefit of SIB RT should be considered." @default.
• W4327694242 created "2023-03-18" @default.
• W4327694242 creator A5018847418 @default.
• W4327694242 creator A5019394129 @default.
• W4327694242 creator A5029172370 @default.
• W4327694242 creator A5034222906 @default.
• W4327694242 creator A5039971014 @default.
• W4327694242 creator A5043293845 @default.
• W4327694242 creator A5047511061 @default.
• W4327694242 creator A5052110520 @default.
• W4327694242 creator A5062612957 @default.
• W4327694242 creator A5083179915 @default.
• W4327694242 creator A5089521164 @default.
• W4327694242 date "2023-09-01" @default.
• W4327694242 modified "2023-09-30" @default.
• W4327694242 title "Neoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal Sarcoma" @default.
• W4327694242 cites W1589353055 @default.
• W4327694242 cites W1849702850 @default.
• W4327694242 cites W1893251984 @default.
• W4327694242 cites W1932953511 @default.
• W4327694242 cites W1951385324 @default.
• W4327694242 cites W1964346268 @default.
• W4327694242 cites W1971211622 @default.
• W4327694242 cites W1987626443 @default.
• W4327694242 cites W2006145539 @default.
• W4327694242 cites W2009873374 @default.
• W4327694242 cites W2010899088 @default.
• W4327694242 cites W2015595598 @default.
• W4327694242 cites W2018224206 @default.
• W4327694242 cites W2021360211 @default.
• W4327694242 cites W2026213869 @default.
• W4327694242 cites W2044899594 @default.
• W4327694242 cites W2051346698 @default.
• W4327694242 cites W2062008907 @default.
• W4327694242 cites W2062076858 @default.
• W4327694242 cites W2062820368 @default.
• W4327694242 cites W2069111865 @default.
• W4327694242 cites W2072861135 @default.
• W4327694242 cites W2081256130 @default.
• W4327694242 cites W2086974359 @default.
• W4327694242 cites W2098225751 @default.
• W4327694242 cites W2117205940 @default.
• W4327694242 cites W2153477869 @default.
• W4327694242 cites W2323526189 @default.
• W4327694242 cites W2325570741 @default.
• W4327694242 cites W2399586251 @default.
• W4327694242 cites W2403514711 @default.
• W4327694242 cites W2417149948 @default.
• W4327694242 cites W2568291593 @default.
• W4327694242 cites W2571362158 @default.
• W4327694242 cites W2767006240 @default.
• W4327694242 cites W2772510259 @default.
• W4327694242 cites W2971414129 @default.
• W4327694242 cites W3042640771 @default.
• W4327694242 cites W3086258129 @default.
• W4327694242 cites W3099626960 @default.
• W4327694242 cites W3108215950 @default.
• W4327694242 cites W3117471412 @default.
• W4327694242 cites W3182879297 @default.
• W4327694242 cites W3186836535 @default.
• W4327694242 cites W4206841660 @default.
• W4327694242 cites W4229445919 @default.
• W4327694242 cites W4229450048 @default.
• W4327694242 cites W4235275268 @default.
• W4327694242 cites W4243642724 @default.
• W4327694242 cites W772589830 @default.
• W4327694242 doi "https://doi.org/10.1016/j.ijrobp.2023.03.037" @default.
• W4327694242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36935026" @default.
• W4327694242 hasPublicationYear "2023" @default.
• W4327694242 type Work @default.
• W4327694242 citedByCount "3" @default.
• W4327694242 countsByYear W43276942422023 @default.
• W4327694242 crossrefType "journal-article" @default.
• W4327694242 hasAuthorship W4327694242A5018847418 @default.
• W4327694242 hasAuthorship W4327694242A5019394129 @default.
• W4327694242 hasAuthorship W4327694242A5029172370 @default.
• W4327694242 hasAuthorship W4327694242A5034222906 @default.
• W4327694242 hasAuthorship W4327694242A5039971014 @default.
• W4327694242 hasAuthorship W4327694242A5043293845 @default.
• W4327694242 hasAuthorship W4327694242A5047511061 @default.
• W4327694242 hasAuthorship W4327694242A5052110520 @default.
• W4327694242 hasAuthorship W4327694242A5062612957 @default.
• W4327694242 hasAuthorship W4327694242A5083179915 @default.
• W4327694242 hasAuthorship W4327694242A5089521164 @default.
• W4327694242 hasConcept C121608353 @default.
• W4327694242 hasConcept C126322002 @default.
• W4327694242 hasConcept C126838900 @default.
• W4327694242 hasConcept C126894567 @default.
• W4327694242 hasConcept C141071460 @default.
• W4327694242 hasConcept C142724271 @default.
• W4327694242 hasConcept C143998085 @default.
• W4327694242 hasConcept C146357865 @default.
• W4327694242 hasConcept C151730666 @default.
• W4327694242 hasConcept C2778256501 @default.
• W4327694242 hasConcept C2778292576 @default.
• W4327694242 hasConcept C2778629024 @default.
• W4327694242 hasConcept C29730261 @default.
• W4327694242 hasConcept C2989005 @default.

• next